Pourya Sarvari

Dr. Pourya Sarvari

NIGEB, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PSPourya Sarvari
Pourya Sarvari
PSPouya Sarvari
Pouya Sarvari
IRIvonne Ramírez-Díaz
Ivonne Ramírez-Díaz
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
Karla RubioKarla Rubio
Karla Rubio
Epigenetic modifications are known to regulate cell phenotype during cancer progression, including breast cancer. Unlike genetic alterations, changes in the epigenome are reversible, thus potentially reversed by epi-drugs. Breast cancer, the most common cause of cancer death worldwide in women, encompasses multiple histopathological and molecular subtypes. Several lines of evidence demonstrated distortion of the epigenetic landscape in breast cancer. Interestingly, mammary cells isolated from breast cancer patients and cultured ex vivo maintained the tumorigenic phenotype and exhibited aberrant epigenetic modifications. Recent studies indicated that the therapeutic efficiency for breast cancer regimens has increased over time, resulting in reduced mortality. Future medical treatment for breast cancer patients, however, will likely depend upon a better understanding of epigenetic modifications. The present review aims to outline different epigenetic mechanisms including DNA methylation, histone modifications, and ncRNAs with their impact on breast cancer, as well as to discuss studies highlighting the central role of epigenetic mechanisms in breast cancer pathogenesis. We propose new research areas that may facilitate locus-specific epigenome editing as breast cancer therapeutics.

12 July 2023 in Global Translational Medicine
Verified
Journal Article
Open access
PDF file
PSPourya Sarvari
Pourya Sarvari
As a pathologically heterogeneous disease, cancer is one of the leading causes of global morbidity. According to the World Health Organization, approximately one in six deaths are caused by cancer. Fortunately, many cancers can be cured if diagnosed at early stages and treated efficiently. Despite the benefits of conventional cancer treatments such as surgery, chemotherapy, hormone therapy, and radiation therapy, they have several drawbacks, including cytotoxicity, inaccurate targeting of tumor cells, and multi-drug resistance, which underscore the importance of developing novel and effective strategies to improve diagnosis, prognosis, therapy, and patient survival. Recently, the advancement of nanotechnology has opened new horizons for cancer treatment thanks to the discovery of nanoparticles (NPs) and the small-sized molecules that revolutionized the drug delivery methods in cancerous tissues. The specific characteristics of NPs, such as reduced toxicity, improved permeability, and accurate targeting of tumor cells, provide a great advantage in cancer treatment and help to overcome the limitations and challenges of conventional cancer treatment methods. Besides, the role of NPs in immunotherapy has created a novel concept for cancer treatment. This review gives a brief overview regarding the importance of NPs and their targeting mechanism, as well as the challenges and limitations associated with their use in cancer treatment.

22 February 2024 in INNOSC Theranostics and Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
PSPourya Sarvari
Pourya Sarvari
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.

24 July 2024 in INNOSC Theranostics and Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
PSPourya Sarvari
Pourya Sarvari
IRIvonne Ramirez-Diaz
Ivonne Ramirez-Diaz
KRKarla Rubio
Karla Rubio
Gene expression regulation is one of the most fundamental cellular processes, enabling the activation of a gene to produce either the translatable protein-coding transcript (mRNA) or a functional non-coding RNA with gene regulatory functions, ultimately determining cell identity and function. Although gene expression regulation can occur at transcriptional, translational, and post-translational levels, transcription initiation is the first and the most important step in gene expression, facilitating the transfer of biological information from DNA to protein. Enhancers and super-enhancers are among the master regulators of tissue- and cell-specific transcription regulation involved in cell differentiation and tumor formation. Despite four decades passing since the first discovery of enhancers in eukaryotes and extensive efforts undertaken to identify enhancers on a genomic scale during the last decade, the discovery of enhancers still faces certain limitations and needs further investigation. The perturbation of enhancer function due to genetic or epigenetic changes is closely linked to a range of human disorders, including the development and progression of cancers. Thus, the detection of early cancer-related enhancer activity and the subsequent normalization of expression abnormalities using enhancer-targeting CRISPR epigenetic editing, as well as enhancer-targeting pharmaceuticals, are regarded as groundbreaking therapeutic tactics in preclinical stages.